| Name | Title | Contact Details |
|---|
Medical Facilities holds controlling interest in five specialty surgical hospitals located in Arkansas, Indiana, Oklahoma, and South Dakota. Medical Facilities` hospitals focus on a limited number of high volume, non-emergency surgical, diagnostic and imaging procedures. The case mix at each hospital is a function of the clinical specialties of the physicians on the medical staff and the equipment and infrastructure at each facility. Orthopedic and neurosurgical procedures represent a large portion of the case volumes at the hospitals. Medical Facilities also holds interest in ambulatory surgery centers located in Arkansas, California, Michigan, Missouri, Nebraska, Ohio, Oregon and Pennsylvania. The centers perform a broad range of outpatient procedures, with patient stays of less than 24 hours.
Zitter Health Insights is a market-leading business intelligence firm serving life science companies, specialty pharmacies and managed healthcare organizations focused on optimizing patient access to pharmaceuticals. The company offers the nation`s largest payer research panel and the largest database of prior authorization policies. The average panel member represents 1 million+ covered lives and the research portfolio covers the entire spectrum of payer-influenced entities. Insights are generated primarily in multi-client subscription formats including: Managed Care Oncology Index, Managed Care Biologics and Injectables Index, Managed Care Benefit Design Index, Prior Authorization Tracking Tool, Managed Care Message Monitor, Co-Pay Offset Monitor, and P&T Perspective. Analysis is conducted for more than 250 manufacturers, 150 therapeutic areas and 1,000 products.
Themis Vision Systems is a Stennis Space Center, MS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tango2 is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TherOx, Inc. (TherOx) is a private, venture-financed medical device company based in Irvine, California, dedicated to elevating the standard of care for treatment of heart attack patients. A heart attack is caused when an artery in the heart becomes blocked. Current treatment of heart attack is to reestablish blood flow in the blocked artery as quickly as possible. Typically, this is done with a combination of medication and a percutaneous coronary intervention (PCI) which may include the placement of a (intracoronary) stent. PCI successfully restores blood flow, but damage to the patient’s heart remains. Blood flow in the microvasculature downstream from the blockage is compromised, and critical heart muscle tissue is damaged – or infarcted – due to oxygen deprivation brought on by the heart attack. The intent of SuperSaturated Oxygen (SSO2) Therapy from TherOx is to salvage damaged heart tissue by placing a high concentration of oxygen (~760 – 1,000 mmHg, or 5 – 7 times normal levels) into the patient’s blood plasma and delivering it directly to the area impacted by the heart attack. SSO2 Therapy serves as a complement to PCI and stenting. Immediately following the interventional procedure, proprietary technology from TherOx mixes a pre-specified concentration of “SuperOxygenated” saline solution with the patient’s blood to produce SuperOxygenated blood. The SuperOxygenated blood is then delivered through a catheter to the oxygen deficient tissue. Company research has confirmed in clinical studies that SuperSaturated Oxygen Therapy has the potential to reverse ischemia and may resuscitate tissue that may otherwise die. SSO2 Therapy circulates the patient`s own blood via the existing arterial access site used for the stenting procedure. Thus, no new access site is required. The TherOx DownStream System and DownStream Cartridge bear the CE Mark but are not available for commercial distribution in the EU at this time.